Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Receivables (2022 - 2025)

Historic Receivables for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $476133.0.

  • bioAffinity Technologies' Receivables fell 6540.64% to $476133.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $476133.0, marking a year-over-year decrease of 6540.64%. This contributed to the annual value of $1.2 million for FY2024, which is 3873.52% up from last year.
  • Latest data reveals that bioAffinity Technologies reported Receivables of $476133.0 as of Q3 2025, which was down 6540.64% from $441385.0 recorded in Q2 2025.
  • bioAffinity Technologies' 5-year Receivables high stood at $1.7 million for Q2 2024, and its period low was $9930.0 during Q3 2022.
  • For the 4-year period, bioAffinity Technologies' Receivables averaged around $724874.0, with its median value being $841227.0 (2023).
  • In the last 5 years, bioAffinity Technologies' Receivables skyrocketed by 1110990.94% in 2023 and then crashed by 7426.31% in 2025.
  • bioAffinity Technologies' Receivables (Quarter) stood at $20978.0 in 2022, then skyrocketed by 3910.04% to $841227.0 in 2023, then surged by 38.74% to $1.2 million in 2024, then plummeted by 59.2% to $476133.0 in 2025.
  • Its Receivables stands at $476133.0 for Q3 2025, versus $441385.0 for Q2 2025 and $981125.0 for Q1 2025.